Citations

Clear

5212 citation(s) found for "Wang, Yu".

Cost-effectiveness of first-line IV vs oral iron for iron-deficiency anemia in women with heavy menstrual bleeding
Wang, Daniel , Singh, Manraj , Ito, Satoko, Ng, Ding Quan , Glaeser-Khan, Samira, Wang, Daniel , Hirniak, Sam , Lee, Alfred Ian , Cuker, Adam, Goshua, George , Sra, Manraj Singh , Glaeser‐Khan, Samira , Cuker, Adam , Goshua, George , Ito, Satoko , Cuker, Adam

Mayo Clinic

Blood Advances | January 8, 2026 | Volume: 10 | Issue: 5 | Pages: 1508-1517

10.1182/bloodadvances.2025018315 | PMID 41504430 Get It

Abstract Iron-deficiency anemia (IDA) affects nearly one-third of women globally, with heavy menstrual bleeding (HMB) being a significant risk factor among those of reproductive age. Despite the substantial burden of HMB-related IDA, patients often face delays in receiving effective treatment. Oral iron is typically used as first-line therapy, despite frequent gastrointestinal side effects and challenges in treatment adherence. This study evaluated the reproductive life span cost-effectiveness of first-line intravenous (IV) vs oral iron therapy for women with HMB and IDA. We developed a Markov model simulating a cohort of women aged 18 to 51 years, comparing first-line treatment with IV iron dextran, IV ferumoxytol, IV iron sucrose, or oral ferrous sulfate. Costs and quality-adjusted life years (QALYs) were estimated from the societal perspective. IV iron dextran was the cost-effective treatment, yielding 19.26 QALYs at a cost of $157 500, compared with 19.10 QALYs at $152 900 for oral ferrous sulfate. The incremental cost-effectiveness ratio for IV iron dextran was $28 600 per QALY. Treatment with IV ferumoxytol and iron sucrose cost $158 300 and $163 500, respectively, and did not provide additional QALY benefit compared with IV iron dextran, which remained the cost-effective treatment across a range of scenarios and sensitivity analyses. Our findings indicate that first-line treatment with IV iron dextran is the cost-effective strategy for managing IDA in women with HMB at commonly accepted willingness-to-pay thresholds. These results support expanding access to IV iron as a first-line option, and highlight the need to reduce treatment delays and insurance-related barriers.
Discovery of potent oligopeptides for various metabolic diseases using deep learning
Xiao, Baichuan , Zhu, H., Ma, Chao , WANG, Xiaoran, Feng, Zhanying, Lang, R. E., Shan, Hailin, Meng, Ziqiu, He, Runbang, Zhou, Yixiang , Huang, J., Wei, Siyang, Liu, D., Liu, Jiqiang, Shi, Zhenni, Tang, Xiaokai , Wang, Jinmo, Liu, Chao, Li, Zhanzhan , Zhang, Yong-Biao, Lang, Ruirui, Wang, Liguo

Mayo Clinic

No container title available | January 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.06.697667 Get It

SUMMARY Artificial intelligence (AI)-based methods are increasingly critical in peptide drug discovery, but their applications are limited in a narrow scope such as antimicrobial peptides. For indications where peptide therapy inherently excels, such as metabolism, endocrinology, and tissue regeneration, AI-based pipeline for therapeutic peptide discovery is long awaited but still unmet. Here, we propose a deep learning-based pipeline, Deepeptide, capable of identifying therapeutic oligopeptides for various metabolism-related indications. Leveraging the intrinsical relationship of ‘disease indication — biological processes — molecular functions’, Deepeptide discovers oligopeptides with indication-ameliorating-related molecular functions as lead candidates for indication of interest. Deepeptide was applied in five representative indications of metabolism, endocrinology, and tissue regeneration: angiogenesis, lipid metabolism, osteogenesis, glucose metabolism, and anti-angiogenesis. Overall, 62% of the identified oligopeptide candidates demonstrated significant bioactivity in vitro, with most of them showing comparable potency to the first-line drugs. Notably, the heptapeptide AP7 exhibited angiogenic potency comparable to VEGF in excisional wound splinting mouse model by promoting cell migration rather than proliferation, and hexapeptide TP6 showed significant dual-efficacy against hyperlipidemia and obesity in high-fat diet mice by inhibiting lipid synthesis and regulating gut microbiota. These findings highlight the potential and generalizability of Deepeptide in therapeutic oligopeptide discovery for metabolic diseases.
Supervised Multimodal Fission Learning
Mao, Lingchao, Wang, Qi , Su, Yi , Lure, Fleming , Chong, Catherine D. , Schwedt, Todd J. , Li, Jing , Mao, Lingchao , Mao, Lingchao , Schwedt, Todd J , Chong, Catherine D

Mayo Clinic

INFORMS Journal on Data Science | January 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1287/ijds.2024.0059 Get It

Learning from multimodal data sets can leverage complementary information and lead to improved performance for prediction tasks. A commonly used strategy to account for feature correlations in high-dimensional data sets is the latent variable approach. Several latent variable methods have been proposed for multimodal data sets; however, these methods either focus on extracting a shared component across all modalities or extracting a shared component and individual components specific to each modality, overlooking correlations within partial subsets of modalities. We propose multimodal fission learning (MMFL), the first supervised latent variable model that adopts a generalizable decomposition into globally joint, partially joint, and individual components from multimodal data sets. A key strength of MMFL is a natural extension to incorporate incomplete multimodal data in either training and test phases by leveraging the learned modality structure. Through simulation studies, we demonstrate that MMFL outperforms a variety of existing multimodal algorithms under both complete modality and incomplete modality settings. We applied MMFL to two real-world case studies: early prediction of Alzheimer’s disease using neuroimaging and genetic data and predicting posttraumatic headache improvement using clinical data collected via questionnaires and brain neuroimaging data. MMFL achieved improved predictive accuracy and enhanced interpretability offering insights for within- and cross-modal relationships of multimodal data sets. History: Rema Padman served as the senior editor for this article. Funding: This research was supported by the National Institutes of Health [Grants 2R42AG053149-02A1, R01AG069453, 30AG072980, R01AG069453, and 1R61NS113315-01], the National Science Foundation [Grant DMS-2053170], and the Department of Defense [Award W81XWH-19-0534]. The grantee organization is the Northern California Institute for Research and Education. In the past, ADNI has also received funding from the National Institute of Biomedical Imaging and Bioengineering, the Canadian Institutes of Health Research, and private sector contributions through the Foundation for the National Institutes of Health including generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. Data Ethics & Reproducibility Note: The code capsule is available at https://github.com/lingchm/MMFL and in the e-Companion to this article (available at https://doi.org/10.1287/ijds.2024.0059 ).
The authors reply:
Tonna, Joseph E. , Tonna, Joseph E. , Wang, Jeffrey Y. , Jentzer, Jacob C.

Mayo Clinic

Critical Care Medicine | January 6, 2026 | Volume: 54 | Issue: 1 | Pages: 216-217

10.1097/ccm.0000000000006977 | PMID 41493366 Get It

Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma
Alderuccio, Juan Pablo , Baggio, Diva , Han, Sunwoo , Nizamuddin, Imran , Saha, Aditi, Dong, Ning , Wang, Yucai, Cherng, Hua‐Jay J. , Wagner-Johnston, Nina D., Desai, Amrita, Geethakumari, Praveen Ramakrishnan , Moyo, Tamara K. , Sandoval‐Sus, Jose , EPPERLA, NARENDRANATH, Kamdar, Manali, Tavarozzi, Rita , Danilov, A., Tun, H., Munoz, Javier, Narkhede, Mayur , Maraj, Adrian Matthew, Osborne, Wendy , Calvert, Victoria, El‐Sharkawi, Dima , Hilali, Ammar, Collins, Graham P., Elmusharaf, Nagah, Santarsieri, Anna , Karim, Farheen, Monick, Sarah, Trutzer, Iris Margalit, Can, Jones, Ayers, Amy , Feo, Jacopo Calabrese De, Ghosh, Nilanjan, Treitman, Rachel, Okcu, Izel, Hann, William D., Barrett, Aisling , Deshani, Vismay, Cwynarski, K., Wang, Yucai , Saha, Aditi , Ghione, Paola , Khwaja, Jahanzaib , Saha, Aditi , Wang, Yucai , Cherng, Hua-Jay J , Tolu, Seda , Wagner-Johnston, Nina , Ollila, Thomas A , Grover, Natalie S , Koff, Jean L , Ramakrishnan Geethakumari, Praveen , Sandoval-Sus, Jose , Epperla, Narendranath , Wallace, Danielle S , Kamdar, Manali , Tun, Han W , Narkhede, Mayur S , Rhodes, Joanna , Okosun, Jessica , El-Sharkawi, Dima , Collins, Graham P , Linton, Kim M , Santarsieri, Anna , Baidoun, Firas , Monick, Sarah E, Calabrese De Feo, Jacopo , Sharp, John , Ghosh, Nilanjan , Okcu, Izel , Hann, William , Barrett, Aisling , Deshani, Vismay , Kahl, Brad S , Chavez, Julio C , Olszewski, Adam J , Ghione, Paola , Dong, Ning, Wagner‐Johnston, Nina D. , Grover, Natalie S. , Koff, Jean L. , Epperla, Narendranath , Wallace, Danielle , Kamdar, Manali , Tun, Han W. , Muñoz, Javier, Rhodes, Joanna , Prica, Anca A. , Kühnl, Andrea , Maraj, Adrian , Smith, Jeff , Calvert, Victoria, Linton, Kim , Baidoun, Firas , Sharp, John , Kallam, Avyakta , Abeyakoon, Chathuri , Kahl, Brad S. , Olszewski, Adam J. , Cwynarski, Kate

Mayo Clinic

Blood | January 5, 2026 | Volume: 147 | Issue: 16 | Pages: 1814-1827

10.1182/blood.2025031455 | PMID 41490516 Get It

Abstract Secondary central nervous system (CNS) large B-cell lymphoma (SCNSL) occurs in the de novo setting, as a CNS-isolated relapse, or synchronous (concomitant CNS and systemic) relapse. SCNSL is a devastating event without therapeutic consensus. Thus, we aimed to evaluate treatment outcomes in an international cohort. Progression-free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR, estimated using competing-risk models) were reported. Prognostic factors were identified in a 6-month landmark multivariate analysis. Outcomes after thiotepa autologous stem cell transplant (ASCT) and chimeric antigen receptor (CAR) T-cell therapy (CAR-T) delivered at relapse were compared after propensity score matching (PSM). A total of 1139 patients were included in the analysis (de novo: 537; relapsed SCNSL: 602). Two-year PFS estimates were 40.4%, 43.9%, and 16.2% for de novo SCNSL, CNS-isolated relapse, and synchronous relapse, respectively. Patients with CNS-isolated relapse demonstrated low rates of systemic recurrence (24-month CIR, 6%). Thiotepa-ASCT correlated with longer survival in de novo SCNSL (PFS: hazard ratio [HR], 0.57; P = .005; and OS: HR, 0.62; P = .023) and CNS-isolated relapses (PFS: HR, 0.55; P = .002; and OS: HR, 0.39; P< .0001). ASCT (thiotepa or no thiotepa) also associated with improved survival in synchronous relapses (PFS: HR, 0.57; P = .023; and OS: HR, 0.48; P = .019). Higher survival with thiotepa-ASCT than CAR-T was observed after PSM (PFS: HR, 0.45; P = .005 and OS: HR, 0.41; P = .014). These data support thiotepa-ASCT in eligible patients, particularly de novo disease and CNS-isolated relapses. CNS-isolated relapse was infrequently associated with systemic recurrence, supporting treatment regimens adopted from primary CNS lymphoma.
Pralsetinib-Induced Lymphocytic Colitis
Jin, Mauricio F. , Tawfic, Sarah, Wang, Xiao Jing (Iris), Tawfic, Sarah S

Mayo Clinic

ACG Case Reports Journal | January 5, 2026 | Volume: 13 | Issue: 1 | Pages: No page available

10.14309/crj.0000000000001943 | PMID 41503171 Get It

ABSTRACT Lymphocytic colitis (LC) is a subtype of microscopic colitis, often associated with chronic watery diarrhea and characterized by an increase in intraepithelial lymphocytes. Although various medications are implicated in drug-induced LC, its incidence as a treatment-related adverse effect of rearrangement during transfection-selective tyrosine kinase inhibitors is not known. We report a case of pralsetinib-induced LC in a patient with stage 3c nonsmall cell lung cancer. This case highlights pralsetinib-induced LC as a cause of persistent diarrhea that is refractory to standard antidiarrheal treatments and prompts gastrointestinal evaluation and histopathological examination to facilitate early diagnosis and management.
Correction to: Atypical Presentations of Levator Ani Syndrome With Perianal Hyperhidrosis: A Case Series
Gupta, Riya , Wang, Xiao Jing (Iris), Jencks, Kara J. , Damianos, John

Mayo Clinic

ACG Case Reports Journal | January 5, 2026 | Volume: 13 | Issue: 1 | Pages: No page available

10.14309/crj.0000000000001948 | PMID 41503174 Get It

Functional Evaluation of TRPC6 Missense Variants in Cancer Patients via Molecular Docking Analysis Compared with Patch Clamp Electrophysiology
Wu, Ying, SUN, XIAOJING , Reddy, Joseph S. , Advani, Pooja , Cerhan, J., Villarraga, Hector R, Asirvatham, Samuel J, Wang, R Y, Lee, H. C., Asirvatham, Samuel J. , Advani, Pooja P, Norton, Nadine , Asirvatham, Samuel J , Wu, Ying, Sun, Xiaojing, Boddicker, Nicholas , Cerhan, James R. , Villarraga, Hector R., Wang, Ru-Xing, Lee, Hon-Chi, Zanchi, Fernando Berton , Lu, Tong

Mayo Clinic

No container title available | January 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.01.697223 | PMID 41509376 Get It

ABSTRACT Gain-of-function mutations in the transient receptor potential 6 (TRPC6) channel have recently been recognized as risk factors for both doxorubicin (DOX)-induced cardiomyopathy. Functional evaluation of TRPC6 missense variants is therefore important for cancer patients undergoing anthracycline treatment. However, traditional electrophysiological methods are labor-intensive and time-consuming. In this study, we compared the functional responses of TRPC6 missense variants to 1-oleoyl-2-acetyl-sn-glycerol (OAG), a TRPC6 agonist, using molecular docking and patch clamp recording techniques. For the wild-type (WT) TRPC6 structure (PDB ID: 6UZ8), OAG exhibited a binding energy of -4.49 kcal/mol and a dissociation constant (Kd) of 0.511 mM. Twenty TRPC6 missense variants were identified from cancer patients in the Mayo Clinic database. Of these, fifteen variants had resolvable structures, nine of which displayed increased Kd values and six decreased Kd values compared to WT in molecular docking analysis. Patch clamp recordings revealed that TRPC6 WT and mutant channels were inactive at baseline but were activated upon 50 μM OAG stimulation, except two loss-of-function variants. Moreover, a 24-h treatment with 0.5 μM DOX significantly enhanced OAG-induced channel activation. All three variants identified in patients with heart failure demonstrated gain-of-function properties in both electrophysiological measurements and in-silico predictions. Importantly, the results obtained from molecular docking and patch clamp recordings were strongly correlated, showing an 82% concordance, higher than the predictions from AlphaMissense. These findings indicate that our computational analysis provides a rapid and reliable method for predicting the functional impact of TRPC6 missense variants, which may aid clinical decision-making in cancer patients receiving chemotherapy.
Validation of 13,102 ICD-10-CM Codes Using a Large Language Model-Based System
Wang, Yichen, Song, Yilin , Siu, Rex K. , Nimma, Induja R., Yan, Yan, Savage, Thomas , Wang, Yiming, Li, Zhichen, Ramai, Daryl , Wang, Jiale , Badurdeen, Dilhana, Tao, Cui, Kumbhari, Vivek , Huang, Yuting, Huang, Yuting , Huang, Yuting , Wang, Jiale

Mayo Clinic

No container title available | December 31, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2025.12.30.25343244 Get It

ABSTRACT Objective To comprehensively evaluate the validity of ICD-10-CM codes for both prevalent diagnoses and less common diseases, and to assess the performance of a large language model (LLM)-based system in validating these codes. Materials and Methods This retrospective study analyzed hospital admissions from the Medical Information Mart for Intensive Care (MIMIC-IV) database. We developed a validated LLM-based system using GPT-4o, refined through iterative prompt engineering, to assess ICD-10-CM code validity. We measured the PPV of ICD-10-CM codes, PPV of principal and secondary diagnoses, and the performance of an LLM-based system in code validation. Results Among 865,079 assigned codes, the PPV was 84.6% (95% CI, 84.5%-84.6%). Principal diagnoses had a PPV of 93.9% (95% CI, 93.7%-94.1%), while secondary diagnoses had a PPV of 83.8% (95% CI, 83.7%-83.9%). The LLM system demonstrated high performance in validating ICD codes, achieving 93.6% accuracy, 95.4% sensitivity and 85.2% specificity. Among correctly assigned secondary diagnoses, the majority (67.9%) represented historical or baseline conditions, while 32.1% reflected active conditions that deviated from baseline status; 22.3% of these emerged after hospital admission. PPV decreases with later diagnosis positions, with the largest decline occurring between principal and secondary diagnoses. Discussion and Conclusion In this large-scale evaluation, ICD-10-CM codes exhibited generally high accuracy, though variability existed by position and condition type. A validated LLM system performed comparably to physician review and offers a scalable means to improve coding accuracy. These findings support the potential for integrating LLM-based auditing into routine workflows to strengthen the quality of administrative and research data.